Microphysiological Systems of Cardiac and Tumor Tissue Derived from Induced Pluripotent Stem Cells
Cancer remains a leading cause of mortality in the United States, and world wide. There remains a need to develop new therapeutic options. While 2-D cell culture systems remain the primary method to screen for new therapeutics due to simplicity, reproducibility, and affordability, these systems do not capture the rich cell-cell and cell-matrix interactions of the 3-D in vivo cancer microenvironment. Moreover, cardiac arrhythmia is the most common life-threatening side effect of anti-cancer drugs. The advent of induced pluripotent stem (iPS) cell technology provides an opportunity to develop patient-specific microphysiological systems (MPS) for personalized medicine. We are developing an MPS that integrates cardiomyocytes, endothelial cells, and stromal cells all derived from the same iPS cell, together with primary tumor tissue.